Sanofi fronts €300M to part­ner up with In­novent on Chi­na mar­ket, eye­ing quick piv­ot to com­mer­cial­iza­tion

Sanofi has found a high-pro­file part­ner in Chi­na to take two of its top can­cer drug prospects through the clin­ic and on­to the big Asian mar­ket. And they’re buy­ing in­to the part­ner’s stock — at a sig­nif­i­cant pre­mi­um — to make that hap­pen.

At the end of the day in Eu­rope, Paris-based Sanofi spot­light­ed a deal with In­novent to ac­quire €300 mil­lion in the Chi­nese phar­ma’s shares, at a 20% markup, with an op­tion on €300 mil­lion more at a lat­er date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER